Home
Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Home
Portfolio
Strategy
Team
News
Careers
Contact
Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders
Read Article
News
2023
2022
Archive
January 5, 2023
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
January 5, 2023
Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
January 5, 2023
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
December 20, 2022
IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board
December 20, 2022
Arvinas Announces Changes to its Board of Directors
December 19, 2022
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
December 15, 2022
Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using Reset®at AAAP
December 15, 2022
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
December 12, 2022
IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161
December 9, 2022
Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th Ga2len Global Urticaria Forum
« Previous Page
1
2
3
4
5
…
106
Next Page »